Cargando…
Mutations Associated with No Durable Clinical Benefit to Immune Checkpoint Blockade in Non-S-Cell Lung Cancer
SIMPLE SUMMARY: With the application of immunotherapy in patients with non-small-cell lung cancer (NSCLC), we found that immunotherapy for some patients cannot achieve long-term effects. Therefore, the purpose of this study is to explore the characteristics of these patients and make a model that ca...
Autores principales: | Zhu, Guangsheng, Ren, Dian, Lei, Xi, Shi, Ruifeng, Zhu, Shuai, Zhou, Ning, Zu, Lingling, Mello, Ramon Andrade De, Chen, Jun, XU, Song |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003499/ https://www.ncbi.nlm.nih.gov/pubmed/33808631 http://dx.doi.org/10.3390/cancers13061397 |
Ejemplares similares
-
Prognostic value of ferroptosis‐related genes in patients with lung adenocarcinoma
por: Zhu, Guangsheng, et al.
Publicado: (2021) -
ARID1A, ARID1B, and ARID2 Mutations Serve as Potential Biomarkers for Immune Checkpoint Blockade in Patients With Non-Small Cell Lung Cancer
por: Zhu, Guangsheng, et al.
Publicado: (2021) -
Deep neural network classification based on somatic mutations potentially predicts clinical benefit of immune checkpoint blockade in lung adenocarcinoma
por: Peng, Jie, et al.
Publicado: (2020) -
Patient Blood Type Is Associated With Response to Immune Checkpoint Blockade in Metastatic Cancer
por: Chen, Ruifeng, et al.
Publicado: (2022) -
Peripheral CD8+ T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma
por: Fairfax, Benjamin P, et al.
Publicado: (2020)